In the irinotecan and cisplatin group , median overall survival was 2.8 years ( 95 % CI 2.4-3 .6 ) ; overall survival did not differ between the two groups ( hazard ratio 1.09 [ 95 % CI 0.80-1 .46 ] , one-sided stratified log-rank p = 0.70 ) .